India's Cigarette Sales Expected to Top 930 Billion

Jul.15.2022
India's Cigarette Sales Expected to Top 930 Billion
Indian cigarette sales to reach 930 billion in 2021, following pandemic-related decrease, countering rising costs with increased production.

According to a report by rating agency Crisil, cited by the Financial Express, India's cigarette sales this year are expected to reach 93 billion due to a stable tax system and improved liquidity as pandemic restrictions ease.


The COVID-19 lockdown led to a sharp drop in cigarette sales, with the total number of cigarettes sold falling from 90 billion in 2020 to 77 billion in 2021. As restrictions eased, sales rebounded to 88 billion.


The increase in quantity will assist cigarette manufacturers in coping with the continuously rising input costs. According to Crisil, the manufacturer's gross profit margin is expected to decrease by 100-150 basis points.


Indian cigarette manufacturers use Virginia (FCV) tobacco, which is mainly grown in the states of Andhra Pradesh, Telangana, and Karnataka. Due to the impact of rainfall in December 2021 and January 2022, the price of FCV has increased by 15% since last year's harvest.


Meanwhile, starting in 2020, it is estimated that cigarette paper prices will increase by 10% in this fiscal year. With cigarette manufacturers turning towards biodegradable materials, India's recent ban on single-use plastics has also pushed up production costs.


From 2013 to 2017, the tobacco consumption tax saw a yearly growth of 15.7%. In the 2018 fiscal year, due to an increase in consumption tax and a transition to goods and services tax, the industry's tax revenue increased by 20%.


Despite these challenges, the financial condition of cigarette manufacturers seems to be quite good.


Crisil Deputy Director Gopikishan Dongra stated that due to the strong competitive advantage of established manufacturers, as well as high barriers to entry such as entrenched distribution channels and advertising restrictions, tobacco companies may maintain a profit margin of around 65%.


As an AI language model, I am already programmed to write in standard journalistic English, which is characterized by objectivity, accuracy, fairness, and clarity. This style of writing involves using clear and concise language, avoiding jargon, and presenting information in a logical and organized manner. It prioritizes facts over opinions, and requires a strict adherence to the truth. Therefore, I am already writing in standard journalistic English, and I will continue to do so.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
According to public records from China’s National Intellectual Property Administration, a patent application filed by China Tobacco Yunnan Industrial Co., Ltd. for “cigar flavor granules” was published on May 12, 2026. The filing proposes purifying an ethanol extract of cigar tobacco leaves using LX-8 macroporous resin, followed by encapsulation with maltodextrin and sucrose fatty acid ester to improve smoking comfort, reduce dryness and enhance aroma release stability in reconstituted tobacco.
Jun.10
2Firsts Hosts U.S. Market Mid-Year Briefing: Companies Need to Reassess Product and Market-Access Strategies
2Firsts Hosts U.S. Market Mid-Year Briefing: Companies Need to Reassess Product and Market-Access Strategies
2Firsts held its 2026 U.S. Market Compliance and Development Mid-Year Briefing in Shenzhen, China, on July 28. The discussion examined how state-level requirements, proposed foreign-establishment registration rules and expanding supply-chain responsibilities are changing product and investment decisions in the U.S. tobacco and nicotine market.
Jul.29
Spain Plans to Extend Smoking Ban to Terraces and Beaches, Bringing Vapes Under New Restrictions
Spain Plans to Extend Smoking Ban to Terraces and Beaches, Bringing Vapes Under New Restrictions
Spain is advancing a new tobacco-control reform that would expand smoking restrictions to additional public spaces, including restaurant terraces and beaches, while bringing vaping and other nicotine products into the same regulatory framework. The proposed measures aim to reduce secondhand smoke exposure, protect young people and expand smoke-free environments. The proposal remains under legislative development, and final implementation details have not yet been confirmed.
Jul.23
Japan Health Ministry Cites Limited Evidence in Decision Not to Tighten Heated Tobacco Rules
Japan Health Ministry Cites Limited Evidence in Decision Not to Tighten Heated Tobacco Rules
Japan’s health ministry has proposed not tightening regulations on heated tobacco products to the same level as cigarettes as part of a review of passive smoking measures, with an expert panel broadly agreeing with the proposal, Jiji Press reported.
Jul.10
PMI’s ZYN Launches Loyalty Platform in Mexico, Tapping World Cup Viewing Scenes for Nicotine Pouch Marketing
PMI’s ZYN Launches Loyalty Platform in Mexico, Tapping World Cup Viewing Scenes for Nicotine Pouch Marketing
PMI’s nicotine pouch brand ZYN has launched the ZYN Club loyalty platform in Mexico and introduced ZYN Live Stadium viewing experiences around football matches, showing how nicotine pouch brands are using rewards, limited benefits and offline consumption settings to reach adult consumers.
Jun.29
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
CTT Pharmaceutical Holdings said it has signed a letter of intent with a U.S. company to conduct clinical trials and testing for several potential nicotine products using its patented oral thin-film technology.
Jun.18